Inhibition of Hmgcr could block tumor cell growth and metastasis [36], but clinical trials with Hmgcr inhibitor (pravastatin) have shown discrepant results [37]–[39], which may be attributed to the genetic heterogeneity of HCCs. Here, HMGCR is linked to neoplasm.